Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure

Efficacy of Aquapheresis in Patients Treated as Outpatients With Decompensated Heart Failure at a Veterans Hospital

With this research the Investigators hope to learn if early aquapheresis in an outpatient setting will improve congestive heart failure symptoms in outpatients with decompensated heart failure who have been refractory to high dose diuretics. In previous trials in inpatient settings, aquapheresis has been demonstrated to improve quality of life and reduce hospital visits for those who have undergone the treatment. This study is one of the first to evaluate the effectiveness of aquapheresis in veterans with congestive heart failure in an outpatient setting.

The aquapheresis device, Aquadex FlexFlow® System, manufactured by CHF Solutions™, Minneapolis, MN, has been approved by the Food and Drug Administration (FDA) for removing excess sodium and fluid from patients suffering from volume overload, like in congestive heart failure.

Study Overview

• Status: Withdrawn
• Conditions: Heart Failure; Congestive Heart Failure; Decompensated Heart Failure
• Intervention / Treatment: Device: Aquapheresis; Drug: IV Diuretics

Detailed Description

Congestive heart failure (CHF) affects nearly 2% of the U.S. population, with almost 1 million hospital admissions for acute decompensated CHF annually. Congestive heart failure is the most frequent cause of hospitalization in patients over the age of 65. Patients admitted for acute decompensated heart failure (ADHF) have a high 6-month readmission rate for acute CHF, ranging from 23% to 40% in different studies. It is estimated that 25 to 30% of these patients are diuretic resistant with 50% of patients losing less than 5 lbs. from admission weight and 20% actually gaining weight during the hospitalization.

Although loop diuretics have not been shown to improve survival in patients with CHF, they effectively alleviate symptoms of congestion. Diuretics have been part of standard CHF therapy in all recent survival trials of β-blockers, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers. Loop diuretics have been shown to be the most effective diuretics as single agents in moderate to severe heart failure. However, loop diuretics may be associated with increased morbidity and mortality attributable to deleterious effects on neurohormonal activation, electrolyte balance, and cardiac and renal function.

Removal of excessive fluid in patients with CHF is usually achieved by a combination of fluid and salt restriction and loop diuretics, but in some cases volume overload persists. Diuretic resistance is common, especially after chronic exposure to loop diuretics; patients require escalating doses (PO or IV to bypass delayed absorption in gut due to bowel edema), addition of another diuretic that works on different part of renal tubules (i.e. Thiazides) +/- diuretic drip and, if still refractory, ultimately Aquapheresis (a form of ultrafiltration).

Aquapheresis (AQ) compared to IV diuretics in the UNLOAD Trial (10), AQ safely produced greater weight loss, fluid removal, and reduction in 90-day readmission rate compared to IV diuretic. A meta-analysis of 10 randomized control trials (RCTs) showed AQ not only to be effective but safe. These observations suggest that a strategy of early ultrafiltration may improve responsiveness to diuretics, quicker weight loss, decrease hospitalization, readmission to hospital, ER or doctor visits with minimal risks. As result of these trials, American Hospital Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of American (HFSA) guidelines state it is reasonable to start Aquapheresis in patients with obvious volume overload or patients who are refractory to high dose diuretics (IIa, LOE B). Moreover, while this therapy is part of standard of care in an inpatient setting, many hospitals as a result of Affordable Care Act (ACA), have taken to AQ on an outpatient setting to further decrease the burden and attended cost associated with management of CHF. But the Investigators are unaware of any other prospective outpatient studies that have looked at the outcomes and cost effectiveness of aquapheresis.

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects must be 18 years of age or older already on standard of care therapy including Angiotensin Converting Enzyme Inhibitors (ACE-I), Angiotensin

Receptor Blockers (ARBs), Sacubitril/Valsartan, beta-blocker, oral diuretic (80 mg Lasix/2 mg Bumex/40 mg Torsemide+/-Thiazide diuretic), and meet the following inclusion criteria to be enrolled:

Inclusion Criteria:

1. CHF refractory to oral diuretic (80mg Lasix, 2mg Bumex, or 40mg Torsemide)

2. Volume overload secondary to systolic or diastolic HF, evidenced by at least 2 of the following:

   1. Elevated BNP (>100)
   2. Paroxysmal nocturnal dyspnea or orthopnea
   3. Elevated jugular venous distention (>/ 7 cm)
   4. X-ray findings consisted with CHF
   5. Presence of ascites or LE edema . -

Exclusion Criteria:

1. Acute Coronary Syndrome
2. Hypertensive urgency or emergency
3. Rapid atrial fibrillation difficult to control
4. Contraindication to anticoagulation
5. Pregnancy
6. Requires hemodialysis (> CR > 3.0 mg/dl)
7. Symptomatic hypotension
8. Poor venous access
9. Pressor dependent. -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Aquapheresis; Per protocol, if randomized to Aquapheresis arm (AQ), all diuretics are discontinued and AQ will be administered as per established protocol. BMP and CBC will be checked prior to initiation and as needed, 7-10 days, 30, 60 and 90 days post discharge. Note, aquapheresis rate is to be decreased by 100 cc/hr if Hgb increases by 1gm/dL, and stopped if rate is decreased to 50 cc/hr or reaches euvolemia, whichever comes first.	Device: Aquapheresis; The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).; Other Names: Hemodialysis; Ultrafiltration
Active Comparator: IV Diuretics; Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If a patient in IV arm is refractory to maximum 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.	Drug: IV Diuretics; Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.; Other Names: Intravenous Diuretics

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Hospitalizations by 7 days post-treatment	Compare number of hospitalization readmissions for CHF between Intervention (Aquaphersis arm) & Control groups	Between outpatient treatment and 7-days after outpatient treatment
Number of Hospitalizations by 30 days post-treatment	Compare number of hospitalization readmissions for CHF between Intervention (Aquaphersis arm) & Control groups	Between outpatient treatment and 30 days after outpatient treatment
Number of Hospitalizations by 60 days post-treatment	Compare number of hospitalization readmissions for CHF between Intervention (Aquaphersis arm) & Control groups	Between outpatient treatment and 60 days after outpatient treatment
Number of Hospitalizations by 90 days post-treatment	Compare number of hospitalization readmissions for CHF between Intervention (Aquaphersis arm) & Control groups	Between outpatient treatment and 90 days after outpatient treatment
Weight change by 7 days post-treatment	Compare weight change (pounds) in patients between Intervention & Control groups	Outpatient treatment to 7 days after outpatient treatment
Weight change by 30 days post-treatment	Compare weight change (pounds) in patients between Intervention & Control groups	Outpatient treatment to 30 days after outpatient treatment
Weight change by 60 days post-treatment	Compare weight change (pounds) in patients between Intervention & Control groups	Outpatient treatment to 60 days after outpatient treatment
Weight change by 90 days post-treatment	Compare weight change (pounds) in patients between Intervention & Control groups	Outpatient treatment to 90 days after outpatient treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total fluid removal	Compare total fluid removal (ml) in patients between Intervention & Control groups	Baseline (Randomization) to outpatient discharge
Blood urea nitrogen at Baseline	Compare Blood urea nitrogen (BUN; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	Baseline (Randomization)
Blood urea nitrogen at 7 days post-treatment	Compare Blood urea nitrogen (BUN; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	7 days after outpatient treatment
Blood urea nitrogen at 30 days post-treatment	Compare Blood urea nitrogen (BUN; mg/dl) (higher than normal range is worse)) in patients between Intervention & Control groups	30 days after outpatient treatment
Blood urea nitrogen at 60 days post-treatment	Compare Blood urea nitrogen (BUN; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	60 days after outpatient treatment
Blood urea nitrogen at 90 days post-treatment	Compare Blood urea nitrogen (BUN; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	90 days after outpatient treatment
Creatinine at Baseline	Compare Creatinine (Cr; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	Baseline (Randomization)
Creatinine at 7 days post-treatment	Compare Creatinine (Cr; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	7 days after outpatient treatment
Creatinine at 30 days post-treatment	Compare Creatinine (Cr; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	30 days after outpatient treatment
Creatinine at 60 days post-treatment	Compare Creatinine (Cr; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	60 days after outpatient treatment
Creatinine at 90 days post-treatment	Compare Creatinine (Cr; mg/dl) (higher than normal range is worse) in patients between Intervention & Control groups	90 days after outpatient treatment
Glomerular filtration rate at Baseline	Compare Glomerular filtration rate (GFR; ml/min/1.73 meters squared) (lower than normal range is worse) in patients between Intervention & Control groups	Baseline (Randomization)
Glomerular filtration rate at 7 days post-treatment	Compare Glomerular filtration rate (GFR; ml/min/1.73 meters squared) (lower than normal range is worse) in patients between Intervention & Control groups	7 days after outpatient treatment
Glomerular filtration rate at 30 days post-treatment	Compare Glomerular filtration rate (GFR; ml/min/1.73 meters squared) (lower than normal range is worse) in patients between Intervention & Control groups	30 days after outpatient treatment
Glomerular filtration rate at 60 days post-treatment	Compare Glomerular filtration rate (GFR; ml/min/1.73 meters squared) (lower than normal range is worse) in patients between Intervention & Control groups	60 days after outpatient treatment
Glomerular filtration rate at 90 days post-treatment	Compare Glomerular filtration rate (GFR; ml/min/1.73 meters squared) (lower than normal range is worse) in patients between Intervention & Control groups	90 days after outpatient treatment
Brain natriuretic peptide (BNP) test at Baseline	Compare BNP (pg/ml of blood) (higher than normal range is worse) in patients between Intervention & Control groups	Baseline (Randomization)
Brain natriuretic peptide (BNP) test at 7 days post-treatment	Compare BNP (pg/ml of blood) (higher than normal range is worse) in patients between Intervention & Control groups	7 days after outpatient treatment
Brain natriuretic peptide (BNP) test at 30 days post-treatment	Compare BNP (pg/ml of blood) (higher than normal range is worse) in patients between Intervention & Control groups	30 days after outpatient treatment
Brain natriuretic peptide (BNP) test at 60 days post-treatment	Compare BNP (pg/ml of blood) (higher than normal range is worse) in patients between Intervention & Control groups	60 days after outpatient treatment
Brain natriuretic peptide (BNP) test at 90 days post-treatment	Compare BNP (pg/ml of blood) (higher than normal range is worse) in patients between Intervention & Control groups	90 days after outpatient treatment
6-minute Walk Test at Baseline	Compare 6-minute Walk Test (meters/6 minutes; less distance means more disability) in patients between Intervention & Control groups	Baseline (Randomization)
6-minute Walk Test at 7 days post-treatment	Compare 6-minute Walk Test (meters/6 minutes; less distance means more disability) in patients between Intervention & Control groups	7 days after outpatient treatment
6-minute Walk Test at 30 days post-treatment	Compare 6-minute Walk Test (meters/6 minutes; less distance means more disability) in patients between Intervention & Control groups	30 days after outpatient treatment
6-minute Walk Test at 60 days post-treatment	Compare 6-minute Walk Test (meters/6 minutes; less distance means more disability) in patients between Intervention & Control groups	60 days after outpatient treatment
6-minute Walk Test at 90 days post-treatment	Compare 6-minute Walk Test (meters/6 minutes; less distance means more disability) in patients between Intervention & Control groups	90 days after outpatient treatment
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)	Compare Minnesota Living with Heart Failure Questionnaire (MLWHFQ) (total score; higher score means more impairment) in patients between Intervention & Control groups	Baseline (Randomization)
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)	Compare Minnesota Living with Heart Failure Questionnaire (MLWHFQ) (total score; higher score means more impairment) in patients between Intervention & Control groups	7 days after outpatient treatment
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)	Compare Minnesota Living with Heart Failure Questionnaire (MLWHFQ) (total score; higher score means more impairment) in patients between Intervention & Control groups	30 days after outpatient treatment
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)	Compare Minnesota Living with Heart Failure Questionnaire (MLWHFQ) (total score; higher score means more impairment) in patients between Intervention & Control groups	60 days after outpatient treatment
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)	Compare Minnesota Living with Heart Failure Questionnaire (MLWHFQ) (total score; higher score means more impairment) in patients between Intervention & Control groups	90 days after outpatient treatment
SF-36 at Baseline	Compare SF-36 weighted sums (0-100 scale; lower score means more disability) in patients between Intervention & Control groups	Baseline (Randomization)
SF-36 at 7 days post-treatment	Compare SF-36 weighted sums (0-100 scale; lower score means more disability) in patients between Intervention & Control groups	7 days after outpatient treatment
SF-36 at 30 days post-treatment	Compare SF-36 weighted sums (0-100 scale; lower score means more disability) in patients between Intervention & Control groups	30 days after outpatient treatment
SF-36 at 60 days post-treatment	Compare SF-36 weighted sums (0-100 scale; lower score means more disability) in patients between Intervention & Control groups	60 days after outpatient treatment
SF-36 at 90 days post-treatment	Compare SF-36 weighted sums (0-100 scale; lower score means more disability) in patients between Intervention & Control groups	90 days after outpatient treatment
Adverse events: bleeding incidents during Outpatient treatment	Compare number of Adverse Events (bleeding incidents) in patients between Intervention & Control groups: bleeding, line-related infection, etc.	Start of treatment to discharge, which is usually the same day, but up to 3 days post-treatment, if medically necessary.
Adverse events: line infections during Outpatient treatment	Compare number of Adverse Events (line infections) in patients between Intervention & Control groups: bleeding, line-related infection, etc.	Start of treatment to up to 14 days post-treatment.
Costs	Compare costs (dollars) between Intervention & Control groups	Baseline (Randomization) to 90 days post-discharge

Collaborators and Investigators

• Sponsor: Ramona Gelzer Bell
• Investigators: Principal Investigator: Ramona Gelzer Bell, MD, James A. Haley Veterans Administration Hospital

Publications and helpful links

General Publications

• Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194. doi: 10.1016/j.cardfail.2010.04.004.
• Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005 Feb;149(2):209-16. doi: 10.1016/j.ahj.2004.08.005.
• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5. No abstract available.
• Polanczyk CA, Newton C, Dec GW, Di Salvo TG. Quality of care and hospital readmission in congestive heart failure: an explicit review process. J Card Fail. 2001 Dec;7(4):289-98. doi: 10.1054/jcaf.2001.28931.
• Hamner JB, Ellison KJ. Predictors of hospital readmission after discharge in patients with congestive heart failure. Heart Lung. 2005 Jul-Aug;34(4):231-9. doi: 10.1016/j.hrtlng.2005.01.001.
• Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000 Jan;139(1 Pt 1):72-7. doi: 10.1016/s0002-8703(00)90311-9.
• Lee WY, Capra AM, Jensvold NG, Gurwitz JH, Go AS; Epidemiology, Practice, Outcomes, and Cost of Heart Failure (EPOCH) Study. Gender and risk of adverse outcomes in heart failure. Am J Cardiol. 2004 Nov 1;94(9):1147-52. doi: 10.1016/j.amjcard.2004.07.081.
• Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999 Jan 21;83(2A):1A-38A. No abstract available.
• Wilcox CS. Diuretics. In: Brenner BM, Rector FC. The kidney. Philadelphia: WB Saunders, 1996: 2299-330.
• Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96(3-4):132-43. doi: 10.1159/000047397.
• Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006 Jan 3;47(1):1-8. doi: 10.1016/j.jacc.2005.07.067. Epub 2005 Dec 15.
• Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13;49(6):675-83. doi: 10.1016/j.jacc.2006.07.073. Epub 2007 Jan 26. Erratum In: J Am Coll Cardiol. 2007 Mar 13;49(10):1136.
• Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology. 2001;96(3-4):144-54. doi: 10.1159/000047398.
• Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001 Oct;38(4):963-8. doi: 10.1016/s0735-1097(01)01479-6.
• Rimondini A, Cipolla CM, Della Bella P, Grazi S, Sisillo E, Susini G, Guazzi MD. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med. 1987 Jul;83(1):43-8. doi: 10.1016/0002-9343(87)90495-5.
• Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003 Jun;9(3):227-31. doi: 10.1054/jcaf.2003.28.
• Agostoni P, Marenzi G, Lauri G, Perego G, Schianni M, Sganzerla P, Guazzi MD. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994 Mar;96(3):191-9. doi: 10.1016/0002-9343(94)90142-2.
• Liang KV, Hiniker AR, Williams AW, Karon BL, Greene EL, Redfield MM. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail. 2006 Dec;12(9):707-14. doi: 10.1016/j.cardfail.2006.08.210.
• Kwok CS, Wong CW, Rushton CA, Ahmed F, Cunnington C, Davies SJ, Patwala A, Mamas MA, Satchithananda D. Ultrafiltration for acute decompensated cardiac failure: A systematic review and meta-analysis. Int J Cardiol. 2017 Feb 1;228:122-128. doi: 10.1016/j.ijcard.2016.11.136. Epub 2016 Nov 9.
• Kazory A. Ultrafiltration Therapy for Heart Failure: Balancing Likely Benefits against Possible Risks. Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1463-71. doi: 10.2215/CJN.13461215. Epub 2016 Mar 31.
• Jain A, Agrawal N, Kazory A. Defining the role of ultrafiltration therapy in acute heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2016 Sep;21(5):611-9. doi: 10.1007/s10741-016-9559-2.
• Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, Gottlieb SS, Jaski BE, Kazory A, Levin AP, Levin HR, Marenzi G, Mullens W, Negoianu D, Redfield MM, Tang WHW, Testani JM, Voors AA. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445. doi: 10.1016/j.jacc.2017.03.528.
• Kazory A, Costanzo MR. Extracorporeal Isolated Ultrafiltration for Management of Congestion in Heart Failure and Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018 Sep;25(5):434-442. doi: 10.1053/j.ackd.2018.08.007.

Study record dates

Study Major Dates

• Study Start (Actual): June 8, 2021
• Primary Completion (Actual): July 27, 2021
• Study Completion (Actual): July 27, 2021

Study Registration Dates

• First Submitted: August 24, 2020
• First Submitted That Met QC Criteria: September 29, 2020
• First Posted (Actual): October 1, 2020

Study Record Updates

• Last Update Posted (Actual): August 30, 2021
• Last Update Submitted That Met QC Criteria: August 24, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Diuresis; Aquapheresis
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Physiological Effects of Drugs; Natriuretic Agents; Diuretics
• Other Study ID Numbers: AQUA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes